Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations (Q40212739)

18 September 2017

Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations (English)

1 reference

18 September 2017

Marianela Perez-Torres

1

1 reference

18 September 2017

Marta Guix

2

1 reference

18 September 2017

Adriana Gonzalez

3

1 reference

18 September 2017

Carlos L Arteaga

4

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Journal of Biological Chemistry

18 September 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

18 September 2017

281

1 reference

18 September 2017

52

1 reference

18 September 2017

40183-40192

1 reference

Epidermal growth factor receptor (EGFR) signaling in cancer

18 September 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Cbl-directed monoubiquitination of CIN85 is involved in regulation of ligand-induced degradation of EGF receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M607958200

21 January 2018

Identifiers

DOI

10.1074/JBC.M607958200

1 reference

18 September 2017

1 reference